medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2009, Number 1

<< Back Next >>

Rev Mex Angiol 2009; 37 (1)

Púrpura fulminante (purpura fulminans) posquimioterapia

Rojas RGA, Sarue SN, Hernández VFX, Velazco JS, Villalobos PA

Language: Spanish
References: 15
Page: 23-27
PDF size: 487.67 Kb.


ABSTRACT

Purpura fulminans is a catastrophic disease characterized by sudden and rapidly spreading hemorr hagic skin lesions, which become confluent and progress to gangrene. The process is associated with extensive intravascular thrombosis at the capillary level. We present a case of purpura fulminans post chemotherapy and sepsis due to Escherichia coli


REFERENCES

  1. Torres R, Ballona R. Púrpura fulminans asociada a defi ciencia de proteína C, proteína S y resistencia a proteína C activada. Dermatol Pediatr 2005; 16: 33 7.

  2. Betrosian A, Berlet T. Purpura fulminans in sepsis. Am J Med Sci 2006; 33: 339 45.

  3. Gast T, Kowal Vern A, An G, et al. Purpura fulminans in an adult patient with Haemophilus influenzae sepsis: case report and review of the literature. J Burn Care Res 2006; 27: 102 7.

  4. Davis M, Dy K, Nelson S. Presentation and outcome of pur pura fulminans associated with peripheral gangrene in 12 patients at Mayo Clinic. J Am Acad Dermatol 2007; 57: 944 56.

  5. Nolan J, Sinclair R. Review of management of purpura ful minans and two case reports. Br J Anaesth 2001; 86: 581 6.

  6. Villavicencio JL, González Cerna JL, Velasco P. Acute vas cular problems of children. In: Ravitch M, Steichen F, Aus ten WG, Scott HW (eds.). Current Problems in Surgery. Vol. 22. Chicago ILL. USA: Year Book Medical Publishers; 1985, p. 58 64.

  7. Frutos MC, Iturrioz MA., González PYE, Arratibel FM, et al. Púrpura fulminante idiopática con déficit transitorio de proteína S. An Esp Pediatr 2001; 55: 369 73.

  8. Manco Johnson M, Knapp Clevenger R. Activated protein C concentrate reverses Purpura fulminans in severe genetic protein C deficiency. J Pediatr Hematol Oncol 2004; 26: 25 7.

  9. Rintala E, Kuppila M, Seppälä O, et al. Protein C substitu tion in sepsis associated purpura fulminans. Crit Care Med 2000; 28: 2373 8.

  10. Perler BA. The effect of statin medications on perioperative and long term outcomes following carotid endarterectomy or stenting. Semin Vasc Surg 2007; 20: 252 8.

  11. Almog Y, Terblanche M. Pleiotropic effects of statins: impli cations for critical care. Contemporary Critical Care 2008; 12: 1 11.

  12. McGown CC, Brookes ZLS. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxide. Br J Anaesth 2007; 98: 163 5.

  13. Hassan Z, Mullins R, Friedman B, Shaver J, et al. Purpura fulminans: a case series managed at a regional burn center. J Burn Care Res 2008; 29: 411 5.

  14. Andreasen T, Green S, Childers B. Massive Infectious Soft Tissue Injury: diagnosis and management of necrotizing fasciitis and Purpura fulminans. Plast Reconstr Surg 2001; 1(107): 1025 35.

  15. Duteille F, Thibault F, Perrot P, et al. Salvaging limbs in cases of severe Purpura fulminans: advantages of free flaps. Plast Reconstr Surg 2006; 118: 681 5.




2020     |     www.medigraphic.com